IL17RA and psoriasis: In a phase III, randomized double-blind placebo-controlled study using Brodalumab (a monoclonal antibody against IL-17RA) on moderate-to-severe plaque psoriasis, more than 70 percent of patients achieved a 75% reduction in psoriasis area severity index at 12 weeks, which is much higher than the placebo group (182).